Fresh evidence that fatty food is bad for our health has come to light: mice fed a lard-based diet over a long period got worse at fighting bacteria in the blood, reveals a thesis from the Sahlgrenska Academy.
The mice fed the lard-based diet derived 60 per cent of their total calories from fat. They were compared with mice fed a low-fat diet, where no more than 10 percent of their calories came from fat. As expected, the mice on the high-fat diet got fatter. A more surprising result was that their immune system was less active. The white blood cells got worse at dealing with bacteria in the blood, which could have contributed to many dying of sepsis.
"Obesity is usually associated with inflammation that does not result from an infection, which simply means that the immune defenses are activated unnecessarily," says doctoral student Louise Strandberg who wrote the thesis. "Ironically, the mice on the high-fat diet seem to have a less active immune system when they really need it."
Overweight people are also at a greater risk of acquiring infection, for example in connection with an operation. In mice, the thesis shows that it is fatty food rather than obesity in itself which affects the ability to fight off sepsis caused by bacteria.
Strandberg has also investigated different variants of three genes that are important for the immune system and noted that several of the gene variants that strengthen immunity also result in less obesity.
"So there are all kinds of links between the immune system on the one hand and obesity and diet on the other," says Strandberg.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.